Int J Med Sci 2009; 6(6):305-311. doi:10.7150/ijms.6.305
Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
1. School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan;
2. Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan;
3. Kobe University Graduate School of Medicine, Kobe, Japan;
4. Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, Kyoto, Japan
Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2009; 6(6):305-311. doi:10.7150/ijms.6.305. Available from http://www.medsci.org/v06p0305.htm
Objective: The effects of replacing cisplatin (CDDP) with cis-diammineglycolatoplatinum (nedaplatin, NDP), a second-generation platinum complex, on the pharmacokinetics of 5-fluorouracil (5-FU) were investigated in Japanese patients with esophageal squamous cell carcinoma, who were treated with a definitive 5-FU/CDDP-based chemoradiotherapy.
Methods: Fifty-six patients were enrolled, 49 treated with CDDP and 7 treated with NDP. A course consisted of continuous infusion of 5-FU at 400 mg/m2/day for days 1-5 and 8-12, infusion of CDDP or NDP at 40 mg/m2/day on days 1 and 8, and radiation at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19, with a second course repeated after a 2-week interval. Plasma concentrations of 5-FU were determined by high performance liquid chromatography at 5 PM on days 3, 10, 38 and45, and at 5 AM on days 4, 11, 39 and 46.
Results and conclusions: The circadian rhythm in plasma concentrations of 5-FU observed in the case of CDDP was altered when NDP was used instead. The clinical response can be predicted by monitoring plasma concentrations of 5-FU in the CDDP group, but not in the NDP group.
Keywords: nedaplatin, chemoradiotherapy, esophageal squamous cell carcinoma, 5-fluorouracil, plasma concentration